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Familial hypercholesterolaemia (FH) is the most common and serious monogenic 
disorder of lipoprotein metabolism that leads to premature coronary heart disease.  
Patients with FH are often under-treated, and many remain undiagnosed. The 
deployment of the FH Australasia Network Registry is a crucial component of the 
comprehensive model of care for FH, which aims to provide a standardised, high-
quality and cost-effective system of care that is likely to have the highest impact on 
patient outcomes. The FH Australasia Network Registry was customised using a 
registry framework that is an open source, interoperable system that enables the 
efficient customisation and deployment of national and international web-based 
disease registries that can be modified dynamically as registry requirements evolve. 
The FH Australasia Network Registry can be employed to improve health services for 
FH patients across the Australasia-Pacific region, through the collation of data to 
facilitate clinical service planning, clinical trials, clinical audits, and to inform clinical 
best practice.
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Familial hypercholesterolaemia (FH) is a relatively common genetic disorder that is 
associated with premature coronary heart disease (CHD) [1, 2]. In Australia, at least 
65,000 people are estimated to have FH with the vast majority of cases remaining 
undiagnosed, and in many diagnosed cases, patients are receiving inadequate 
treatment [1, 3]. A patient registry to store clinical and family data is essential to the 
effective provision of services [4-7], and is therefore a vital component of the FH 
model of care for Australasia [3] and integrated guidance of care for FH [8]. A recent 
global ‘call to arms’ by the European Atherosclerosis Society FH Studies 
Collaboration also emphasises the importance of FH registries worldwide [9].
The Registry Framework
Recently, we presented an open source disease Rare Disease Registry Framework 
(RDRF), that allows the efficient deployment of web-based registries that can be 
modified dynamically as requirements evolve [10, 11]. The RDRF empowers registry 
administrators to construct registries with minimal software developer effort, by 
allowing users to dynamically create all data elements (DEs) that define a patient 
registry and to share DEs across registries. Registries are described in a computer-
readable text file, which allows a registry definition to be imported/exported, 
versioned, and stored in a shared accessible environment. 
The RDRF takes a conceptual approach to the design and development of 
patient registries to ensure access, security, privacy, and to meet the need for 
harmonisation across multiple clinical sites in a given country, or internationally. The 
RDRF also fulfills the key criteria required for sustainable registry development [12-
15], and continues to evolve since first described by Bellgard et al. [10, 11, 13, 16].
We describe the deployment of the FH Australasia Network Registry utilising 
the RDRF. The primary purpose of the FH Australasia Network Registry is to collate 
data to facilitate clinical service planning, and to inform clinical best practice [4]. The 
registry will also enable research on aggregated data, and the identification of eligible 
volunteers for clinical trials.
Materials and Methods












Governance and access to patient data
The FH Australasia Network Registry is governed by a National Advisory Board 
appointed from expert members from Australia and New Zealand of the FH 
Australasia Network, which is a subcommittee of the Australasian Atherosclerosis 
Society. The National Advisory Board, which has a Chairman and a Custodian 
elected by members of the Board, oversees the governance of the registry and is 
responsible for all registry activities and reviewing all requests for access to data. All 
projects sanctioned by the Board are conditional on approval by a recognised 
authoritative body in the relevant jurisdiction in which the investigation will be 
undertaken. Access to the registry is co-ordinated by the registry co-ordinator 
(assigned by the National Advisory Board) who is responsible for overarching data 
curation, cross-site co-ordination, and arranging processes for data extraction. The 
registry co-ordinator provides access to the registry through the provision of password 
protected user accounts to authorized data curators.
The FH Australasia Network Registry includes individuals diagnosed with 
FH, individuals with suspected FH, children of individuals with diagnosed FH, and 
undiagnosed family members of individuals diagnosed with or suspected to have FH. 
The registry links index patients to family relatives through the Family Linkage and
Patient Relatives modules. 
Recruitment to the FH Australasia Network Registry began in January 2015, 
co-ordinated through the registry co-ordinator lending support to each jurisdictional 
clinical service. Patients with a diagnosis of FH from participating clinics in Australia 
and New Zealand were provided with a FH Registry Information and Consent Form 
(available from https://fhregistry-international.com/). After providing consent, 
patients were registered and assigned to a “working group”, which is their 
jurisdictional clinical service. The RDRF has multiple levels of access (Appendix A), 
with the ability to assign different users to selected working groups. Only the registry 
co-ordinator has administration privileges, and therefore access to patient data from 
all jurisdictions. 
Requests for access to data by third-parties are regulated through the National 
Advisory Board. Provision of de-identified data is subject to approval by a 
jurisdiction human research ethics committee, recommendation by the National 
Advisory Board, approval of the data custodian (assigned by the National Advisory 
Board) and the study objectives being aligned with Registry objectives.












Ethics Committee and governance approvals were obtained for each clinical 
service site prior to registering patients for the registry. There are no costs to 
registrants or their family members.
System architecture, registry deployment and security
The FH Australasia Network Registry is web-based and accessed from 
https://fhregistry-international.com/. The RDRF is built on top of Django 1.8 (www. 
djangoproject.com/), utilising PostgreSQL (www.postgresql.org/), MongoDB
(www.mongodb.org/), HTML, CSS, YAML (www.yaml.org/), Javascript, jQeury 
(jquery.com/) and Bootstrap (getbootstrap.com/). The RDRF is typically deployed via 
Docker containers (www.docker.com) using uWSGI (uwsgi-docs.readthedocs.org/) 
and nginx (nginx.org/). Django provides distinct levels of inbuilt security, including 
secure socket layer (SSL) security (encrypts all web traffic to and from the 
application), cross-site request forgery (CSRF) checking, login restrictions of all 
views, with the RDRF utilising the Django secure package middleware with all 
settings enabled by default. The RDRF also stores identifying patient demographic 
data in a distinct database to any clinical data (Fig. 1) [11, 13, 16]. The source code 
for the RDRF is available at https://github.com/muccg/rdrf.
Capture of patient data
The demographics and clinical information for each patient are captured by the 
‘Demographics’ and ‘Consents’ modules and six additional Forms titled Clinical 
Data, Medications, Genetic Data, Imaging, Apheresis and Follow Up (Fig. 2). 
Currently, all DEs requested by the International FH Consortium are included in the 
FH Australasia Network registry (see Appendix B for a detailed list of all current 
Data Elements). 
New features and enhancements
Several new features have been developed in the RDRF (see Appendix A), including:
i) Dynamic Consent and Validation; Consent sections and questions are now 
dynamically defined for each registry, and validation and applicability rules may also 
be applied.












ii) Patient Relatives Module; Each Patient Relative is linked to an Index 
Patient through the ‘Patient Relatives Table’, which aides in tracking the results of 
cascade family screening.
iii) Family Linkage Module; Aides in viewing all relatives of an Index Patient 
and their relationships. It also allows Patient Relatives to be promoted to an index (in 
the case an index patient requests to be removed from the registry). 
iv) FH Pedigree Module; Collates information on the number of first, second, 
and third degree relatives, and allows a file containing a family pedigree to be 
uploaded and stored. This section is configured to appear only on the Demographics 
Form of Index Patients. There is potential for a pedigree-drawing tool to be developed 
and included in the registry at a later date. 
Conclusions
The FH Australasia Network Registry provides supporting infrastructure in 
four key areas: i) addressing a current gap in the flow of data for measuring the 
quality of healthcare; ii) supporting basic research through the provision of high-
quality, de-identified data; iii) enabling geographically equitable access to clinical 
trials; and iv) promulgating information about best practice and care services [4]. The 
valuable data captured by this registry will inform research, clinical decision making, 
educational programmes, and ultimately improve the quality of care for FH patients.
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Figure Legends
Figure 1: The Rare Disease Registry Framework: Data is encrypted both at rest and in 
transit and stored in PostgreSQL and MongoDB. Demographic data is stored in a 












separate and distinct database to phenotypic and clinical data. All web traffic to and 
from the application is encrypted. Multi-level access and configurable permissions 
allow different user groups to log into the registry.
Figure 2: Modular structure and functions of the FH Australasia Network Registry. 
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